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DC-specific	ICAM3-grabbing	non-integrin	(DC-SIGN),	which	is	expressed	on	DCs,	can	interact	with	a	vari-
ety	of	pathogens	such	as	HIV-1,	hepatitis	C,	Ebola,	cytomegalovirus,	Dengue	virus,	Mycobacterium,	Leishma-
nia,	and	Candida albicans.	We	demonstrate	that	human	milk	can	inhibit	the	DC-SIGN–mediated	transfer	of	
HIV-1	to	CD4+	T	lymphocytes	as	well	as	viral	transfer	by	both	immature	and	mature	DCs.	The	inhibitory	
factor	directly	interacted	with	DC-SIGN	and	prevented	the	HIV-1	gp120	envelope	protein	from	binding	to	
the	receptor.	The	human	milk	proteins	lactoferrin,	α-lactalbumin,	lysozyme,	β-casein,	and	secretory	leuko-
cyte	protease	inhibitor	did	not	bind	DC-SIGN	or	demonstrate	inhibition	of	viral	transfer.	The	inhibitory	
effect	could	be	fully	alleviated	with	an	Ab	recognizing	the	Lewis	X	(LeX)	sugar	epitope,	commonly	found	in	
human	milk.	LeX	in	polymeric	form	or	conjugated	to	protein	could	mimic	the	inhibitory	activity,	whereas	
free	LeX	sugar	epitopes	could	not.	We	reveal	that	a	LeX	motif	present	in	human	milk	can	bind	to	DC-SIGN	and	
thereby	prevent	the	capture	and	subsequent	transfer	of	HIV-1	to	CD4+	T	lymphocytes.	The	presence	of	such	
a	DC-SIGN–binding	molecule	in	human	milk	may	both	influence	antigenic	presentation	and	interfere	with	
pathogen	transfer	in	breastfed	infants.
Introduction
DCs can capture an array of infectious agents and present their 
antigens to T lymphocytes. DCs express, among other receptors, 
the DC-specific ICAM3-grabbing non-integrin (DC-SIGN) recep-
tor, a C-type lectin, which contains an external calcium-dependent 
mannose-binding lectin domain (1, 2). DC-SIGN interacts with 
the envelope glycoprotein gp120 of HIV-1, HIV-2, and SIV (3–8), 
as well as other pathogens such as hepatitis C (9, 10), Ebola (11), 
cytomegalovirus (12), Dengue virus (13), Mycobacterium (14–16), 
Leishmania (17, 18), Candida albicans (19), and Helicobacter pylori (20, 
21). DC-SIGN has been implicated as playing an important role 
in HIV-1 transmission and the establishment of infection (4, 6, 
22–25). The interaction of HIV-1 with DC-SIGN can lead to infec-
tion of the DCs, or alternatively the virus can be internalized into a 
trypsin-resistant compartment prior to undergoing transfer to its 
main target cells, and this mechanism has been shown to greatly 
enhance infection of T cells in vitro (26, 27).
Mother-to-child transmission (MTCT) of HIV-1 accounts for the 
majority of HIV-1 infections among children (28). Transmission 
can occur either in utero, intrapartum, or through breastfeeding 
(29). It has been recognized that HIV-1 transmission via breast-
feeding accounts for 40% of all MTCTs of HIV-1 (30, 31). Relatively 
little is known with regard to HIV-1 present within human milk 
and how the virus is transmitted from mother to child. Children 
exposed to HIV-1 through breastfeeding will encounter both free 
viral particles as well as cell-associated virus (32, 33). Macrophages 
in human milk are found at varying concentrations during lacta-
tion (34) and are preferentially infected with viruses that utilize the 
CCR5 coreceptor for viral entry (R5) and that are typically associat-
ed with HIV-1 transmission (35, 36). Mammary epithelial cells are 
present in human milk, and these cells are predominantly infected 
with viruses utilizing the CXCR4 coreceptor (X4), virus strains that 
seldom undergo transmission (37, 38). CD4+ T lymphocytes are 
also present in human milk, and these cells can be infected with 
both R5 and X4 strains, depending on the cellular phenotype and 
cell activation status (39, 40). MTCT of HIV-1 via breastfeeding is 
likely to require the transfer of virus across a mucosal barrier or 
via breaches in the mucosal surface. The interaction of the HIV-1 
gp120 protein with DCs, shown to be present at high concentra-
tions in the tonsils, the upper rim of the esophagus (41, 42), and 
the intestinal tract (43), may therefore heighten virus capture and 
transmission. Although DC-SIGN expression has not been ana-
lyzed on DCs from all the above-mentioned anatomical sites, high 
levels of expression have been reported in tonsil material (6).
Several of the proteins present in human milk have been shown 
to posses antimicrobial activity. Lactoferrin (44–46), lysozyme 
(47), and secretory leukocyte protease inhibitor (SLPI) (48, 49) 
have all been shown to exhibit anti–HIV-1 properties in vitro. On 
the contrary, β-casein has been shown to enhance HIV-1 infection 
of CD4+ T lymphocytes (44). Oligosaccharides present in human 
milk include lactodifucotetraose; lacto-N-fucopentaose (LNFP) 
I, II and III; and monofucosyllacto-N-hexaose III; among others 
(50–52). A number of sugar epitopes to be found in human milk 
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are composed of the Lewis group of antigens, including Lewis X 
(LeX) and Lewis Y (LeY) (53), which can be part of a larger oligosac-
charide, regardless of whether the sugar is protein associated or 
not. The LeX epitope (Galβ1-4[Fucα1-3]GlcNAc-R) is also includ-
ed within the LNFP III sugar moiety. This same sugar epitope 
has been identified in bodily fluids, including saliva, blood, and 
human milk and has also been shown to be present in a number 
of pathogens (21) and pathogen extracts (54). Some of the human 
milk oligosaccharides have been shown to protect against toxins 
and pathogens involved in childhood diseases (55).
Results
The effect of human milk on direct HIV-1 infection of CD4+ T lymphocytes 
and DC-SIGN–mediated HIV-1 transfer. We investigated the effect of 
human milk on direct infection of CD4+ T lymphocytes by incu-
bating HIV-1 in the presence of several dilutions of human milk 
from an HIV-1–negative donor taken 6 months into lactation. The 
2-fold dilution of human milk demonstrated a significant degree 
of viral inhibition (>90%; P < 0.05) in comparison with the PBS con-
trol (Figure 1A), which corresponds with previous reports (44–49). 
We also identify an enhancement to infection at the 1:10 dilution 
similar to findings from a previous study (38). Preincubation of 
the same human milk sample (1:2) with HIV-1 before addition 
to CD4+ T lymphocytes (Figure 1B) showed no inhibitory effect 
in comparison to the PBS control, indicating that the inhibition 
shown in Figure 1A is not due to a direct virucidal effect of the milk 
and that the effect is likely conferred on the CD4+ lymphocyte. The 
experiments were repeated with human milk from 2 other moth-
ers, with equivalent results obtained (data not shown).
DC-SIGN–expressing cells can enhance infection of CD4+ T 
lymphocytes (4, 8). To study the effect of human milk on DC-
SIGN–mediated transfer of HIV-1, we utilized the Raji cell line 
expressing the DC-SIGN receptor (Raji-DC-SIGN) (8). The same 
human milk sample as used in the direct infection assay or PBS 
spiked with HIV-1 primary isolates was incubated with the Raji-
DC-SIGN cells for 30 minutes or 2 hours, after which the cells were 
washed and incubated with activated CD4+ T lymphocytes and the 
culture monitored for viral replication. Raji-DC-SIGN cells pre-
incubated with PBS spiked with HIV-1 showed efficient transfer 
to CD4+ T lymphocytes (Figure 2A, black line). The Raji cell line 
not expressing DC-SIGN showed no viral transfer, demonstrat-
ing that the effect we observed is DC-SIGN dependent (data not 
shown). Surprisingly, preincubation of Raji-DC-SIGN cells with 
HIV-1–spiked human milk significantly reduced or blocked trans-
fer of HIV-1 depending on the incubation time (Figure 2A, gray 
line). Through testing cell viabilities, we demonstrated that the 
observed inhibition was not due to induced cell death of Raji-DC-
SIGN by human milk (data not shown). The transfer experiment 
revealed that human milk blocks the transfer of HIV-1 by Raji-DC-
Figure 1
Direct infection of CD4+ T lymphocytes in the presence of human milk. 
(A) PBS or several dilutions of human milk from an uninfected mother 
were spiked with LAI (X4) and added to CD4-enriched T lymphocytes. 
After a 2-hour incubation, the CD4+ T lymphocytes were washed, and 
fresh medium was added. (B) LAI (X4) was incubated with a 1:2 dilu-
tion of human milk or PBS for 2 hours, after which several dilutions 
were made and added to CD4+ T lymphocytes. For both experiments 
the CA-p24 concentration was determined on day 7. *P < 0.05 com-
pared with the PBS control.
Figure 2
DC-SIGN–dependent transfer of HIV-1 to CD4+ T lymphocytes is inhib-
ited in the presence of human milk. (A) A 1:2 dilution of human milk of 
an uninfected mother or PBS was spiked with primary isolates NSI-18 
(R5) or SI-19 (X4) before addition to Raji-DC-SIGN cells. After an incu-
bation of 30 minutes or 2 hours, the cells were washed, and activated 
CD4+ T lymphocytes were added. Viral replication was measured on 
days 7, 9, 12, and 14 after infection by determining CA-p24 values 
using a standard ELISA. The bars represent maximum and minimum 
CA-p24 values. (B) PBS or serial dilutions of human milk were spiked 
with JR-CSF (R5) or LAI (X4) before addition of Raji-DC-SIGN cells; 
after an incubation of 2 hours, the cells were washed with PBS, and 
stimulated CD4+ T lymphocytes were added. At day 7, CA-p24 con-
centrations were determined by standard ELISA. Percent inhibition 
was determined in reference to the CA-p24 concentration of the cor-
responding spiked PBS control.
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SIGN cells irrespectively of viral coreceptor phenotype. We next 
performed limiting dilutions of the same human milk sample and 
found that R5 and X4 HIV-1 variants were completely inhibited at 
a 1:128 but not at a 1:512 dilution (Figure 2B). Similar results were 
observed with the same assays using human milk from 2 other 
HIV-1–negative donors (data not shown).
Human milk compound(s) bind to DC-SIGN, thereby preventing transfer 
of HIV-1 to CD4+ T lymphocytes. To determine whether the inhibitory 
effect of human milk on Raji-DC-SIGN–mediated viral transfer was 
caused by interaction of human milk with HIV-1 or DC-SIGN, we 
conducted preincubation experiments of either Raji-DC-SIGN cells 
or HIV-1 with human milk. To test for binding of the inhibitory 
factor to Raji-DC-SIGN cells, we preincubated the cells with either a 
known inhibitory concentration of human milk (1:4) or PBS before 
washing and then adding virus and subsequently CD4+ T lympho-
cytes. Alternatively, to test binding of components in human milk 
to the virus, we incubated a high-titer virus stock with either PBS 
or human milk, after which the Raji-DC-SIGN cells were added, 
thereby diluting the milk to a noninhibitory concentration (1:667); 
CD4+ T lymphocytes were then added. Preincubation of virus with 
human milk demonstrated a slight reduction in viral transfer com-
pared with the PBS control (Figure 3A), likely reflecting residual 
inhibitory effects of the human milk. In contrast, preincubation 
of the Raji-DC-SIGN cells with human milk provided a highly sig-
nificant reduction in viral transfer compared with the PBS control 
(P < 0.01; Figure 3B). To test whether the observed inhibition was 
due to downmodulation of DC-SIGN expression, we investigated 
the surface expression of DC-SIGN in the presence of human milk. 
We demonstrate that with 2 DC-SIGN–specific mAbs, AZN-D2 
and anti-stalk 4, cell surface expression was not altered, whereas 
Figure 3
The human milk compound(s) interact with the DC-SIGN receptor, 
which does not lead to DC-SIGN downmodulation. (A) Human milk 
(1:4) or PBS was preincubated with a high-titer stock of LAI before add-
ing to Raji-DC-SIGN cells at a dilution known not to inhibit viral replica-
tion. After incubation, the cells were washed, and CD4+ T lymphocytes 
were added, with CA-p24 values measured on day 15 by standard 
ELISA (P > 0.01). (B) Human milk (1:4) or PBS were incubated with 
Raji-DC-SIGN, after which the cells were washed to remove unbound 
human milk components before addition of LAI. After incubation, the 
cells were washed again, and CD4+ T lymphocytes were added, with 
the CA-p24 values measured on day 15 by standard ELISA. *P < 0.01. 
(C) Raji-DC-SIGN cells were incubated with TSM or human milk (1:2) 
before the binding of AZN-D1, AZN-D2, and anti-stalk 4 DC-SIGN–
specific Abs were determined. The filled histograms represent the iso-
type control; the black lines represent the Ab binding without human 
milk preincubation; and the dotted lines represent the Ab binding after 
the cells were incubated with human milk.
Figure 4
DC-SIGN-Fc binding ELISA and the gp120 bead adhesion assay dem-
onstrate the interaction of the human milk compound(s) with DC-SIGN. 
(A and B) Raji-DC-SIGN cells or iDCs, respectively, were incubated 
with human milk (1:20) before addition of fluorescent gp120–coated 
beads. DC-SIGN–positive cells and mock Raji cells were incubated with 
buffer as controls. To determine the specificity of the observed bind-
ing, the cells were incubated with AZN-D1, EGTA, and mannan before 
addition of the gp120 beads. *P < 0.05 compared with the PBS control. 
(C) Human milk (1:20) was coated before addition of DC-SIGN-Fc. The 
specificity of the observed binding was determined by the preincuba-
tion of DC-SIGN-Fc with AZN-D1 and EGTA. **P < 0.01 compared with 
the noninhibitory control. (D) Raji cells expressing the L-SIGN recep-
tor were incubated with buffer, human milk (1:20), AZN-D1, AZN-D2, 
or mannan before addition of the gp120 fluorescent beads. #P < 0.01 
compared with the binding without an inhibitor.
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the binding of AZN-D1 was reduced when DC-SIGN cells were 
preincubated with human milk (Figure 3C). These results suggest 
that the inhibitory effect is mediated via the binding of factor(s) 
in human milk to the DC-SIGN molecule and prevention of its 
interaction with HIV-1 as opposed to the downmodulation of the 
DC-SIGN molecule at the cell surface.
To show direct binding of human milk compound(s) to DC-
SIGN, we introduced 2 previously described assays (6, 56), the 
gp120 bead adhesion assay and the DC-SIGN-Fc binding ELISA. 
In the gp120 bead adhesion assay, the effect of human milk on the 
binding of gp120-coated fluorescent beads to cellular DC-SIGN 
was studied. The binding of the gp120 beads to both Raji-DC-SIGN 
and immature DCs (iDCs) was inhibited by human milk in com-
parison with the control (P < 0.01; Figure 4, A and B, respectively). 
To demonstrate DC-SIGN–specific binding, the cells were preincu-
bated with a DC-SIGN–specific Ab (AZN-D1), the DC-SIGN–bind-
ing sugar mannan, and the Ca2+ chelator EGTA. These agents were 
found to block binding of gp120 beads to the DC-SIGN–express-
ing cells to the same extent as human milk (Figure 4, A and B). To 
confirm the direct interaction of DC-SIGN with human milk, we 
performed a DC-SIGN-Fc binding ELISA where we demonstrated 
that DC-SIGN-Fc binding to human milk was specific, since prein-
cubation of DC-SIGN-Fc with AZN-D1 or EGTA completely abro-
gated binding (P < 0.01; Figure 4C).
The liver and lymph node–specific homolog of DC-SIGN (liver 
and lymph node–specific ICAM3-grabing non-integrin [L-SIGN]) 
is also capable of interacting with HIV-1 and enhancing viral infec-
tivity (57). To investigate the effect of human milk on the interac-
tion of L-SIGN and gp120, we incubated Raji cells expressing the 
L-SIGN molecule (Raji-L-SIGN) with human milk in the gp120 
bead adhesion assay, and as a control, the cells were preincubated 
with AZN-D1, AZN-D2 (an L-SIGN–specific Ab), mannan, and 
EGTA. The results demonstrated that human milk did not inhibit 
the interaction of gp120 with L-SIGN (Figure 4D), indicating a 
specificity of the human milk compound for DC-SIGN.
Human milk inhibits both iDC- and mature DC–dependent transfer of 
HIV-1.	To	study the biological relevance of the inhibitory prop-
erties of human milk, we utilized a previously described single-
cycle HIV-1 transmission assay (58) using both iDCs and mature 
DCs (mDCs). Either iDCs or mDCs [matured by poly d(I-C)] were 
incubated with several dilutions of human milk before addi-
tion of HIV-1 LAI (X4) and target cells. After 24 hours, luciferase 
activity was measured, representing transmission of HIV-1 to the 
LuSIV cells. Human milk was found to inhibit HIV-1–mediated 
transfer by both iDCs and mDCs (Figure 5A) in a dose-dependent 
manner, with the 2- and 5-fold dilutions showing significant inhi-
bition for both cell types (P < 0.01). Washing after the preincuba-
tion of mDCs with human milk (1:2) before addition of HIV-1 
also showed a significant reduction (P < 0.01) in HIV-1 transfer in 
comparison to the PBS control (data not shown), indicating that 
the observed inhibition shown in Figure 5A was not due to a direct 
virucidal effect of the human milk. We also demonstrated that a 
1:2 and 1:5 dilution of human milk significantly reduces HIV-1 
capture by iDCs (P < 0.01; Figure 5B). We also tested for DC-SIGN 
downmodulation through cell-surface staining with the different 
Abs directed against DC-SIGN (AZN-D1, AZN-D2, and anti-stalk 
4) in the presence or absence of human milk. Both AZN-D2 and 
anti-stalk 4 showed no significant difference in binding before 
and after human milk exposure, indicating that the DC-SIGN 
receptor is not downmodulated by the interaction with human 
milk (Figure 5C), while AZN-D1 does show a reduced binding 
after human milk exposure. We expect that similar results would 
Figure 5
Human milk inhibits the transfer of HIV-1 by iDCs 
and mDCs. (A) Both iDCs and mDCs from the same 
donor were incubated with several dilutions of human 
milk for 30 minutes before addition of LAI (X4). After 
2 hours the cells were washed, and LuSIV cells were 
added; after 24 hours the LuSIV cells were washed, 
and the luciferase activity was determined as described 
in Methods. The asterisks represent statistical differ-
ences in infections (P < 0.05). (B) After an incubation 
of iDCs with human milk or PBS, the cells were washed 
and LAI was added. After an incubation of 2 hours, the 
cells were washed again, and captured CA-p24 levels 
were monitored via ELISA. **P < 0.05 compared with 
the corresponding control value for both experiments. 
(C) iDCs were incubated with TSM or human milk (1:2) 
before the binding of AZN-D1, AZN-D2, and anti-stalk 4 
DC-SIGN–specific Abs were determined. The filled his-
tograms represent the isotype control; the black lines 
represent the Ab binding without human milk preincu-
bation; and the dotted lines represent the Ab binding 
after the cells were incubated with human milk.
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be obtained with an R5 virus and a CCR5-expressing cell, since we 
demonstrated that R5 and X4 viruses are equally inhibited with 
human milk (Figure 2).
Major human milk proteins do not bind DC-SIGN nor inhibit HIV-1 
transfer to CD4+ T lymphocytes. Since inhibition by human milk is 
present at relatively high dilutions (Figure 2B), we hypothesized 
that one of the major proteins present in human milk may be 
responsible for the activity. We therefore tested human lactofer-
rin, bovine β-casein, human lysozyme, human α-lactalbumin, and 
human SLPI, which have been shown to posses modulatory effects 
on HIV-1 replication in vitro (44–49). All these compounds were 
tested in the gp120 bead adhesion assay and the DC-SIGN-Fc bind-
ing ELISA (Figure 6). None of the tested human milk compounds 
could inhibit gp120 binding to Raji-DC-SIGN or iDCs (Figure 
6, A and B, respectively). Furthermore, DC-SIGN-Fc showed no 
binding to the selected milk compounds (Figure 6C). As a control, 
bovine lactoferrin was used, which has previously been shown to 
bind DC-SIGN and prevent viral transfer (58).
Preincubation of human milk with an anti-LeX Ab lifted the inhibition 
of HIV-1 transfer. Since DC-SIGN can bind sugars, we hypoth-
esized that one of the abundant sugar motifs in human milk may 
provide the inhibitory activity (50–52). The fact that we demon-
strated that gp120 binding to L-SIGN could not be inhibited with 
human milk (Figure 4D) and it is known that L-SIGN does not 
bind LeX motifs, we predicted that LeX could be contributing to 
the observed inhibition. To test our hypothesis, we preincubated 
human milk with an anti-LeX IgM Ab or an IgM isotype control 
before use in the culture transfer assay. The results demonstrated 
a dose-dependent lifting of the inhibitory effects of human milk 
on viral transfer after a preincubation with the LeX-specific Ab but 
not with the control Ab (Figure 7A). In contrast, the gp120 bead 
adhesion assay did not show reduced binding of DC-SIGN with 
LeX Ab (data not shown). The most likely explanation for this dif-
ference is that the low-affinity LeX-specific Ab was unable to block 
the high-avidity interaction of cellular multimeric DC-SIGN to 
the unknown human milk component. The DC-SIGN-Fc bind-
ing ELISA (Figure 7B) demonstrated a reduction in DC-SIGN-Fc 
binding after preincubation of the coated human milk with the 
LeX-specific Ab but again not with the control Ab. These results 
indicate that LeX is critical for the human milk compound that 
binds to the DC-SIGN molecule.
Not all LeX-containing complexes can inhibit HIV-1 interacting with 
the DC-SIGN receptor. We tested several compounds containing 
Figure 6
The major milk proteins are not responsible for the inhibitory effect of 
human milk. (A and B) Raji-DC-SIGN cells or iDCs were incubated 
with the major milk proteins before addition of fluorescent gp120–
coated beads; control cells were incubated with buffer. To determine 
the specificity of the observed binding, the cells were incubated with 
AZN-D1, EGTA, and mannan before addition of the gp120 beads. The 
asterisks represent P < 0.01 compared with noninhibitory control. (C) 
The major milk proteins were coated on ELISA plates, and DC-SIGN-
Fc binding was measured. To determine the specificity of the observed 
binding, the DC-SIGN-Fc was preincubated with AZN-D1 and EGTA. 
*P < 0.01 compared with both the AZN-D1 and EGTA control. In all 
experiments the major proteins were diluted to a 1:20 dilution of their 
physiological concentration in human milk.
Figure 7
Incubation of human milk (1:20) with LeX IgM Ab relieves the inhibitory 
properties of human milk on DC-SIGN–mediated transfer of HIV-1 to 
CD4+ T lymphocytes. (A) A 1:200 dilution of human milk was incu-
bated alone, with IgM control Ab (4,000 ng/ml), or with serial dilutions 
of LeX IgM Ab (4,000 to 32.7 ng/ml) before addition of Raji-DC-SIGN 
cells. LAI was added, and following a short incubation, the cells were 
washed, and activated CD4+ T lymphocytes were added, with CA-p24 
values determined at day 7. *P < 0.05 compared with the Raji-DC-
SIGN control. (B) Human milk (1:200) was coated and preincubated 
with anti-LeX IgM Ab (4,000 ng/ml) or an IgM control Ab (4,000 ng/ml) 
before addition of DC-SIGN-Fc to determine binding. DC-SIGN-Fc was 
preincubated with AZN-D1and EGTA to determine the specificity of the 
observed binding. **P < 0.01 compared with the human milk binding 
without Ab present.
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one or more LeX epitopes for inhibitory and DC-SIGN binding 
activity. In the transfer culture assay, LeX coupled to biotinylated 
polyacrylamide (PAA-LeX) and LeX-BSA were both able to inhibit 
DC-SIGN–mediated HIV-1 transfer (Figure 8A). On the contrary, 
both LNFP III, a LeX-containing oligosaccharide present in human 
milk, and the LeX trisaccharide itself were unable to prevent HIV-1 
transfer (Figure 8A), even though LNFP III has been shown previ-
ously to bind DC-SIGN (59). The compounds were also tested in 
the gp120 bead adhesion assay, but none of the tested compounds 
were able to block the interaction between DC-SIGN and gp120 
(data not shown). Most likely, PAA-LeX and LeX-BSA are able to 
block the trimeric gp120 interaction, while binding of DC-SIGN 
to monomeric gp120 expressed on the fluorescent beads is still 
possible. Due to the inability to coat saccharides onto plates in the 
DC-SIGN-Fc binding ELISA, we only tested LeX-BSA and the BSA 
control. LeX-BSA indeed demonstrates binding to DC-SIGN-Fc, 
whereas BSA showed no binding, indicating that the DC-SIGN-Fc 
binding is LeX specific (Figure 8B).
Discussion
C-type lectins, such as the DC-SIGN molecule, expressed on DCs 
have been postulated to play an important role in HIV-1 transmis-
sion and the establishment of initial HIV-1 infection (1, 2, 4, 6, 
22–25). The interaction of DC-SIGN with the HIV-1 gp120 surface 
antigen can result in the efficient presentation of the virus to its 
target cells and can greatly heighten infection and virus replica-
tion (4, 6, 22–25). This mechanism is likely to play a role in MTCT 
of HIV-1 through breastfeeding, since virus transfer is required 
across a mucosal barrier. Virus present in human milk will likely 
encounter DCs situated at high concentrations within the tonsils, 
the esophagus (41, 42), and the intestines (43) that will thereby 
aid virus capture and subsequent transfer to CD4+ lymphocytes at 
the site of infection or in localized lymph nodes. In this study we 
demonstrate that human milk has a strong inhibitory effect on 
the DC-SIGN–mediated transfer of HIV-1 to CD4+ T lymphocytes, 
with R5 and X4 viruses being inhibited to the same extent. A com-
ponent in human milk is interacting with the DC-SIGN molecule 
that prevents HIV-1 from binding to the receptor. We showed that 
lactoferrin, α-lactalbumin, lysozyme, β-casein, and SLPI were not 
responsible for the observed inhibition of HIV-1 interaction with 
DC-SIGN, even though these proteins can alter the direct infection 
of CD4+ T lymphocytes in vitro (44–49). Our results demonstrat-
ing that multimeric and protein-associated LeX motifs can mimic 
the inhibitory activity of human milk and that the activity could 
be alleviated with a mAb recognizing the LeX epitope suggest that a 
LeX component in human milk is providing for the inhibition.
In the majority of our experiments, we utilized the DC-SIGN–
expressing cell line (Raji-DC-SIGN) and the control Raji cell lack-
ing DC-SIGN in order to demonstrate the DC-SIGN specificity 
of our results (8). We have also shown that human milk inhib-
its transfer of HIV-1 by both iDCs and mDCs, illustrating the 
biological relevance of the phenomenon, again with the inhibi-
tion being due to prevention of binding rather than DC-SIGN 
downmodulation. The expression levels of DC-SIGN have previ-
ously been shown to be higher on iDCs than mDCs (60); however, 
the human milk inhibited viral transfer by both cell types. This 
result indicates that the observed inhibition of mDC-dependent 
transfer may reflect the ability of human milk to block transfer 
of HIV-1 by other C-type lectins, such as the mannose receptor 
or the unidentified trypsin-resistant receptor (61). Whether the 
same LeX-containing compound(s) or whether other sugar motifs 
in human milk can bind to other C-type lectin receptors remains 
to be determined. We did demonstrate, however, that the binding 
of HIV-1 to the DC-SIGN homolog L-SIGN is not inhibited by 
human milk. Our result corresponds with the previous observa-
tion that LeX present in Schistosoma mansoni egg antigens (54) is 
able to interact with DC-SIGN but not with L-SIGN (62), recon-
firming LeX as a candidate for the observed inhibition of DC-
SIGN–mediated transfer of HIV-1.
PAA-LeX and LeX-BSA successfully inhibited the DC-SIGN–
mediated transfer of HIV-1. Conversely, both monomeric LeX 
trisaccharide and LNFP III, a human milk sugar, do not inhibit 
viral transfer. Even though LNFP III has been shown previously to 
bind to DC-SIGN (59), this interaction does not lead to sufficient 
blocking of the HIV-1 interaction with DC-SIGN nor prevent viral 
transfer to CD4+ T lymphocytes. Multimeric LeX was not able to 
inhibit gp120-coated beads binding to cellular DC-SIGN, possi-
bly due to the high avidity of this interaction or the difference in 
interaction of the monomeric expression of gp120 on the fluores-
cent beads in comparison to trimeric expression of gp120 on the 
HIV-1 particle. The observed difference in the ability of LeX Ab to 
block the inhibitory effect of human milk in the Raji-DC-SIGN 
transfer assay and the ELISA assay is possibly the result of differ-
ences in DC-SIGN configuration. On the cell surface, DC-SIGN 
is present as a tetramer, whereas in the DC-SIGN-Fc ELISA, the 
receptor is most likely a monomer or dimer, possibly leading to a 
weaker interaction. These differences in the configurations of the 
DC-SIGN molecules tested in the different assays suggest that cau-
tion should be applied when interpreting the results. It has been 
reported in previous studies that the LeX and the gp120 binding 
sites are distinct but overlapping (54, 56, 63). An explanation for 
our observed inhibition by human milk could be that the larger 
Figure 8
Multimeric and protein-associated LeX inhibits DC-SIGN–mediated viral 
transfer. (A) Several LeX-containing compounds showed a difference in 
their ability to block DC-SIGN–dependent transfer of HIV-1 to CD4+ T 
lymphocytes. The LeX trisaccharide, LNFP III, PAA-LeX, LeX-BSA, and 
control BSA were tested in the Raji-DC-SIGN culture transfer assay 
at concentrations of 10 µg/ml. The inhibition is depicted as a percent-
age of the Raji-DC-SIGN incubated with PBS. (B) LeX-BSA and BSA 
as a control were coated before addition of DC-SIGN-Fc to determine 
the binding. DC-SIGN-Fc was preincubated with AZN-D1and EGTA to 
determine the specificity of the observed binding. *P < 0.01 compared 
with both the AZN-D1 and EGTA control.
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compounds block the interaction of gp120 and DC-SIGN through 
steric hindrance by the larger tail. DC-SIGN forms a tetrameric 
structure on the cell surface (1) which could also cause occlusion 
of the gp120 binding site by interaction of several LeX residues with 
different monomeric DC-SIGN receptors. Most likely the interac-
tion of several LeX motifs with the tetrameric DC-SIGN leads to a 
much stronger interaction of the compound and again prevents 
sufficient binding of gp120 and subsequent viral transfer.
It has been previously demonstrated that DC-SIGN can interact 
with an array of other pathogens, including hepatitis C (9, 10), 
Ebola (11), cytomegalovirus (12), and Dengue virus (13), as well 
as Mycobacterium (14–16), Leishmania (17, 18), Candida albicans 
(19), and Helicobacter pylori (20, 21). Interaction of LeX-contain-
ing human milk compounds with DC-SIGN may influence the 
immune responses mounted in the child to incoming patho-
gens by preventing their interaction with the DCs and thereby 
prevent the presentation of pathogen-specific antigens and the 
subsequent activation of CD4+ T lymphocytes. This may be a 
mechanism whereby levels of immune activation are buffered in 
a newborn to prevent overstimulation of the immune system or 
to skew specific immune responses in a certain direction. Indeed, 
it has previously been reported that mice immunized intranasally 
with LNFP III–HSA demonstrated a stronger induction of Th2-
type immune responses versus Th1 (64). This result corresponds 
with the fact that LeX-positive Helicobacter pylori interactions with 
DC-SIGN can block Th1-induced cell responses, which results in a 
relative enhancement of the Th2 cell response (21), suggesting that 
LeX compounds can influence the immune responses generated 
and that LeX compounds in human milk can function as immu-
nomodulatory factors. It will therefore be interesting to investi-
gate whether breastfed versus bottle-fed infants have differences 
in their immune responses mounted against orally transmitted 
pathogens. It has also been reported that the baseline activation 
of lymphocytes is higher in bottle-fed than in breastfed infants 
(65). A number of explanations have been hypothesized, including 
differences in exposure to foreign proteins or a higher variety in 
intestinal microflora. Another possibility is that human milk com-
pounds containing the LeX motif buffers the immune response by 
binding DC-SIGN and that these compounds are absent in for-
mula or cow milk.
Future work will have to determine the biological significance 
of the interaction of the LeX-containing compounds with DC-
SIGN with regard to the stimulation of the immune system and 
the relevance for MTCT of HIV-1 and other pathogens. Further 
identification and characterization of the specific LeX-containing 
compound(s) interacting with DC-SIGN may have major implica-
tions for the development of antimicrobial agents aiming at pre-
venting HIV-1 transmission not only through breastfeeding but 
also through sexual activity.
Methods
Cells. The Raji control cell line and the cell lines expressing either DC-SIGN 
(Raji-DC-SIGN) or L-SIGN (Raji-L-SIGN) were cultured as previously 
described (4). PBMCs were isolated from buffy coats by standard Ficoll-
Hypaque density centrifugation, activated with phytohemagglutinin (3 
µg/ml), and cultured in RPMI medium containing 10% FCS, penicillin (100 
units/ml), and streptomycin (100 units/ml). On day 3 the cells underwent 
CD4+ enrichment by incubation with CD8 immunomagnetic beads (Dynal 
Biotech) and were negatively selected according to the manufacturer’s 
instructions and cultured with IL-2 (100 U/ml). DCs for the single-cycle 
transmission assay were generated from fresh PBMCs with cells layered on 
a standard Percoll gradient (Amersham Pharmacia). The light fraction with 
predominantly monocytes was collected, washed, and seeded in 24-well 
or 6-well culture plates at a density of 5 × 105 cells or 2.5 × 106 per well, 
respectively. After 60 minutes at 37°C, the adherent cells were cultured to 
obtain iDCs in Iscove’s modified Dulbecco’s medium (IMDM) with genta-
micin (86 µg/ml) and 10% fetal clone serum (HyClone) supplemented with 
GM-CSF (500 U/ml) and IL-4 (250 U/ml). Culture medium was refreshed 
on day 3, with cell maturation induced at day 6 by culturing with poly(I:C) 
(20 µg/ml; Sigma-Aldrich). After 2 days, mature CD14–CD1b+CD83+ DCs 
were obtained, washed, and utilized. The culture conditions for LuSIV cells 
with an integrated long terminal repeat–luciferase reporter construct have 
been described previously (66).
Viruses. Replication-competent HIV-1 stocks were generated by the pas-
sage of viruses through CD4+ lymphocytes, with tissue culture infectious 
dose (TCID50/ml) determined by limiting dilution on CD4+-enriched lym-
phocytes (67). Subtype B molecular cloned viruses JR-CSF (R5), LAI (X4), 
and SF-162 (R5) and subtype B primary isolates NSI-18 (R5) and SI-19 (X4) 
were used in the experiments.
Human milk fractions and commercial milk products. Internal review board 
approval was not required because samplings were taken from discarded 
material from a single time point. Human milk samples were sequentially 
centrifuged at 400 g and 530 g for 10 minutes, with pipette removal of the 
lipid layers. Samples were sterilized by filtration through both 0.45-µm 
and 0.2-µm syringe filters (Schleicher & Schuell BioScience Inc.) and stored 
at –80°C. Human lactoferrin (Sigma-Aldrich), bovine lactoferrin (Sigma-
Aldrich), human α-lactalbumin (Sigma-Aldrich), bovine β-casein (NIZO 
Food Research), human lysozyme (Sigma-Aldrich), LNFP III (Calbiochem), 
SLPI (Sigma-Aldrich), LeX trisaccharide (Calbiochem), LeX-BSA, 14-atom 
spacer (Calbiochem), PAA-LeX (Syntesome), anti-human LeX (mouse) IgM 
(Calbiochem), and anti-human ARA-LAM (mouse) IgM were used. All com-
pounds were utilized at physiologically relevant concentrations by dilution 
in PBS containing 10% FCS.
Direct HIV-1 infection assay. Enriched CD4+ lymphocytes were plated in 96-
well plates at 1 × 105 cells/well in IL-2–containing culture medium. Cells 
were incubated for 2 hours with human milk diluted in PBS containing 
10% FCS and spiked with 3.7 log TCID50/ml of HIV-1. After 2 hours the 
cells were washed and fresh medium added. Alternatively, after a 2-hour 
incubation of human milk with HIV-1, the spiked milk was diluted with 
PBS containing 10% FCS before addition to CD4+ T lymphocytes. On day 7 
of culture, viral capsid (CA-p24) levels were determined by ELISA.
DC-SIGN–mediated HIV-1 transfer assay. The Raji and Raji-DC-SIGN cells 
were plated at 2 × 104 cells/well in a 96-well format. Dilutions of human 
milk or human milk compounds were made in PBS containing 10% FCS 
and spiked with 3.7 log TCID50/ml of the appropriate virus before addi-
tion to the Raji-DC-SIGN cells. As a control, PBS containing 10% FCS 
was spiked with the same TCID50/ml of the corresponding virus before 
addition to Raji or Raji-DC-SIGN cells. After incubation the culture was 
washed with PBS before addition of CD4+-enriched T lymphocytes at a 
concentration of 1 × 105 cells/well, with CA-p24 determined on day 7.
DC-SIGN–specific Ab binding after exposure to human milk. Human milk 
was incubated with 50 × 103 Raji-DC-SIGN or iDCs for 15 minutes at 
37°C, after which the cells were washed with TSM (20 mM Tris, 150 mM 
NaCl, 1 mM CaCl2, 2 mM MgCl2) and the cells were incubated at 4°C 
for 45 minutes with 5 µg/ml of the specific DC-SIGN Ab, AZN-D1 (6), 
AZN-D2 (12), or anti-stalk 4. Subsequently, the cells were washed and 
incubated with goat anti-mouse FITC for 45 minutes at 4°C. The cells 
were washed and resuspended in 100 µl TSM containing 0.5% BSA (Frac-
tion V, Fatty Acid-Free; Calbiochem), and the adhesion was measured by 
flow cytometry (BD Biosciences).
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DC-SIGN binding assay. For preincubation of HIV-1 with human milk, a 1:4 
dilution of human milk or PBS containing 10% FCS was incubated with a 
high virus titer (5.6 log TCID50/ml) of SF-162 for 1 hour at 37°C before dilut-
ing the mixture to 1:667 by addition of 0.27 × 106 Raji-DC-SIGN cells in a 
24-well format. The cells were incubated for 2 hours at 37°C before wash-
ing with PBS and addition of CD4+ T lymphocytes at a concentration of 
1 × 106 cells/ml followed by measuring CA-p24 production on day 15. For 
preincubation of Raji-DC-SIGN cells with human milk, a dilution of the 
human milk (1:4) or PBS containing 10% FCS was incubated with 0.27 × 106 
Raji-DC-SIGN cells in a 24-well format for 1 hour at 37°C before washing 
with PBS and addition of SF-162 (2.8 log TCID50/ml). The cells were incubat-
ed for 2 hours before washing and adding 1 × 106 cells/well of CD4+-enriched 
lymphocytes, with CA-p24 production measured on day 15.
gp120 bead adhesion assay. Beads were prepared as previously described 
(6). In short, streptavidin was covalently coupled to carboxylate-modified 
TransFluoSpheres (488/645 nm excitation/emission, 1.0 µm; Invitrogen 
Corp.). The streptavidin beads were incubated with biotinylated F(ab′)2 
fragment goat-anti-human IgG (6 µg/ml; Jackson ImmunoResearch 
Laboratories Inc.) and subsequently incubated overnight with gp120-Fc 
chimera. Fifty thousand Raji-DC-SIGN cells, iDCs, or Raji-L-SIGN cells 
were preincubated with human milk or milk compounds, AZN-D1 (6), 
AZN-D2 (12), EGTA, or mannan for 30 minutes at room temperature. 
The ligand-coated beads (20 beads/cell) were added to the preincubated 
cells and incubated for 30 minutes at 37°C, after which the cells were 
washed with TSM containing 0.5% BSA. After washing, the cells were 
resuspended in 100 µl TSM-BSA buffer, and the adhesion was measured 
by flow cytometry (BD Biosciences).
DC-SIGN-Fc binding ELISA. This assay utilized the DC-SIGN-Fc chime-
ra, which contained the extracellular portion of DC-SIGN (amino acids 
64–404) fused at the C terminus to a human IgG1 Fc fragment as previ-
ously described (56). Human milk or human milk compounds were diluted 
in 0.2 M NaHCO3, coated on ELISA plates (Maxisorp plate; Nunc), and 
incubated overnight at 4°C or 2 hours at 37°C. This was followed by block-
ing with TSM containing 1% BSA for 30 minutes at 37°C before addition 
of soluble DC-SIGN-Fc (5 µg/ml) for 2 hours at room temperature; the 
binding was determined by incubation of a peroxidase-labeled anti-IgG1 
Ab for 30 minutes at room temperature. DC-SIGN-Fc binding specificity 
was determined by preincubation of the DC-SIGN-Fc with either 50 µg/ml 
DC-SIGN–specific mouse Ab AZN-D1 (6) or 10 mM EGTA.
Single-cycle-replication transmission assay. The assay was performed as previ-
ously described (58). In short, mDCs and iDCs were incubated in a 96-well 
plate (35 × 103 to 50 × 103 DCs/well) with human milk for 30 minutes at 
37°C before addition of virus (5 ng CA-p24/well), which was incubated for 
2 hours at 37°C. The DCs were washed twice with PBS before addition of 
50 × 103 LuSIV cells. After 24 hours, LuSIV cells were harvested and resus-
pended in 50 µl lysis buffer (25 mM Tris-Cl 7.8, 2 mM DTT, 2 mM CDTA, 
10% glycerol, 1% Triton X-100). The cells were then incubated for 45 min-
utes at room temperature while shaking, followed by 10 minutes centrifu-
gation at 3,200 g. The supernatant was transferred to a white-solid 96-well 
plate (Costar; Corning), and 150 µl of buffer (100 µg/ml BSA, 6.6 mM ATP, 
15 mM MgSO4, 25 mM glycylglycine) was added. One hundred microliters 
of DE(-)Luciferin (Roche Diagnostics GmbH) was injected per well (0.28 
mg/ml lucibuffer excluding ATP). LuSIV cells (50 × 103) grown without DC 
or HIV-1 were used to obtain the background luciferase value.
Capture assay. To measure the capture of HIV-1 by iDCs, the cells were 
incubated in a 96-well plate (50 × 103 DCs/well) with human milk for 30 
minutes at 37°C before addition of the virus (5 ng CA-p24/well), which 
was incubated for 2 hours at 37°C. The iDCs were washed twice with PBS 
before the CA-p24 concentration was determined by standard ELISA.
Statistics. All statistical comparisons were performed using ANOVA. 
P < 0.01 and P < 0.05 were considered statistically significant.
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